Changes of plasma fibroblast growth factor-21 (FGF-21) in oral glucose tolerance test and effects of metformin on FGF-21 levels in type 2 diabetes mellitus

Endokrynologia Polska

Volumn 64, Issue 3, 2013, Pages 220-224

  Zhang, Mei ^a   Liu, Ying ^a   Xiong, Zhong Yun ^a   Deng, Zhi Yong ^a   Song, Hao Lan ^a   An, Zhen Mei ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Fibroblast growth factor 21; Metformin; OGTT; Type 2 diabetes

Indexed keywords

FIBROBLAST GROWTH FACTOR 21; INSULIN; METFORMIN;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLUCOSE METABOLISM; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PROTEIN BLOOD LEVEL; SEX DIFFERENCE;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; FIBROBLAST GROWTH FACTORS; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED;

EID: 84880469413     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Kharitonenkov A, Shiyanova TL, Koester A et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005; 115: 1627-1635.
2. Xu J, Lloyd DJ, Hale C et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009; 58: 250-259.
3. Kharitonenkov A, Wroblewski VJ, Koester A et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007; 148: 774-781.
4. Coskun T, Bina HA, Schneider MA et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008; 149: 6018-6027.
5. Chen WW, Li L, Yang GY et al. Circulating FGF-21 levels in normal subjects and in newly diagnose patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2008; 116: 65-68.
6. Zhang M, Xiong ZY, Zeng L et al. [Plasma fibroblast growth factor-21 and abdominal obesity]. Sichuan Da Xue Xue Bao Yi Xue Ban 2010; 41: 487-489, 522.
7. Eto K, Tumenbayar B, Nagashima S et al. Distinct association of serum FGF21 or adiponectin levels with clinical parameters in patients with type 2 diabetes. Diabetes Res Clin Pract 2010; 89: 52-57.
8. Cuevas-Ramos D, Almeda-Valdes P, Gomez-Perez FJ et al. Daily physical activity, fasting glucose, uric acid, and body mass index are independent factors associated with serum fibroblast growth factor 21 levels. Eur J Endocrinol 2010; 163: 469-477.
9. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
10. Xu J, Stanislaus S, Chinookoswong N et al. Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin resistant mouse models - association with liver and adipose tissue effects. Am J Physiol Endocrinol Metab 2009; 297: E1105-E1114.
11. Arner P, Pettersson A, Mitchell PJ et al. FGF21 attenuates lipolysis in human adipocytes - a possible link to improved insulin sensitivity. Febs Lett 2008; 582: 1725-1730.
12. Kharitonenkov A, Shanafelt AB. Fibroblast growth factor-21 as a therapeutic agent for metabolic diseases. Biodrugs 2008; 22: 37-44.
13. Zhang X, Yeung DC, Karpisek M et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008; 57: 1246-1253.
14. Matuszek B, Lenart-Lipińska M, Duma D et al. Evaluation of concentrations of FGF-21 - a new adipocytokine in type 2 diabetes. Pol J Endocrinol 2010; 61: 50-54.
15. Chen C, Cheung BM, Tso AW et al. High plasma level of fibroblast growth factor 21 is an Independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects. Diabetes Care 2011; 34:2113-2115.
16. Li K, Li L, Yang M et al. Effects of rosiglitazone on fasting plasma fibroblast growth factor-21 levels in patients with type 2 diabetes mellitus. Eur J Endocrinol 2009; 161: 391-395.
17. Boyle JG, Logan PJ, Jones GC et al. AMP-activated protein kinase is activated in adipose tissue of individuals with type 2 diabetes treated with metformin: a randomised glycaemia-controlled crossover study. Diabetologia 2011; 54: 1799-1809.
18. Sokolovska J, Isajevs S, Sugoka O et al. Influence of metformin on GLUT1 gene and protein expression in rat streptozotocin diabetes mellitus model. Arch Physiol Biochem 2010; 116: 137-145.
19. Chau MD, Gao J, Yang Q, Wu Z, Gromada J. Fibroblast growth factor 21 regulates energy metabolism by activating the AMPKSIRT1-PGC-1alpha pathway. Proc Natl Acad Sci USA 2010; 107: 12553-12558.
20. Hou YT, Li JN, Ren GP et al. Cloning, expression and glucose regulation activity of human FGF-21. Yi Chuan 2010; 32: 583-587.
21. Garanty-Bogacka B, Syrenicz M, Goral J et al. Changes in inflammatory biomarkers after successful lifestyle intervention in obese children. Pol J Endocrinol 2011; 62: 499-505.
22. Jankiewicz-Wika J, Kołomecki K, Cywiński J et al. Impact of vertical banded gastroplasty on body weight, insulin resistance, adipocytokine, inflammation and metabolic syndrome markers in morbidly obese patients. Pol J Endocrinol 2011; 62: 109-119.
23. Lin Z, Zhou Z, Liu Y et al. Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese. PLoS One 2011; 6: e18398.